Advances in Immunotherapy for Non-Small-Cell Lung Cancer
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Immunology".
Deadline for manuscript submissions: 20 September 2025 | Viewed by 1401
Special Issue Editor
Interests: molecular oncology; immunotherapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Lung cancer is the leading cause of cancer-related death worldwide, with non-small-cell lung cancer (NSCLC) being the primary type. The chemotherapy standard for advanced disease generally consists of a platinum agent in combination with a second drug, such as paclitaxel and nab‐paclitaxel. Unfortunately, it is often diagnosed at advanced stages, when therapy leaves patients with a very poor prognosis.
The discovery of immune checkpoints and subsequent development of Nobel Prize-winning immune checkpoint inhibitors (ICIs) have brought in a radical revolution in the therapeutic landscape of lung cancer, specifically NSCLC. The landscape of immunotherapy in lung cancer is rapidly expanding, and ICIs have become the standard-of-care treatment for patients with metastatic, locally advanced, and resectable NSCLC, with remarkable improvement in overal survival.
In this Special Issue, we invite investigators to contribute original research or review articles that highlight recent important advances in immunotherapy for NSCLC. Potential topics include, but are not limited to, the following:
- Genomic and proteomic characteristics of NSCLC and immunotherapy;
- Tumor microenvironment and immontherapy of NSCLC;
- Single/combination immunotherapy in NSCLC;
- Side effects of immunotherapy in NSCLC.
Dr. Raheleh Roudi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- non-small cell lung cancer
- immunotherapy
- immune checkpoint inhibitors
- PD-1
- PD-L1
- pembrolizumab
- nivolumab
- atezolizumab
- CTLA4
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
